Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Plaintiffs of Iressa cancer drug case

TOKYO, Japan - Three deceased patients' relatives who sued the Japanese government and the Japanese unit of British pharmaceutical company AstraZeneca PLC, demanding compensation for the side effects caused by the lung cancer drug Iressa, walk to the Tokyo High Court on Nov. 15, 2011. The high court on the same day ruled the government and AstraZeneca K.K. are not responsible for damages, overturning a lower court ruling. The plaintiffs sought a combined 77 million yen in compensation.

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Supporters of plaintiffs hold up banners in front of the Osaka District Court on Feb. 25, 2011, declaring victory in their case after the court ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine of 11 plaintiffs who sought compensation over side-effects caused by the lung cancer drug Iressa.

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Hideki Shimizu (R), a plaintiff who demanded compensation over side effects caused by the lung cancer drug Iressa, speaks at a press conference in Osaka on Feb. 25, 2011, together with Akio Chikazawa, a plaintiff in a similar suit filed in Tokyo. The Osaka District Court the same day ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine out of 11 plaintiffs, including Shimizu.

E

Kin sue state, distributor over side-effects of Iressa cancer drug

TOKYO, Japan - Akio Chikazawa speaks to reporters in Tokyo on Nov. 25 after filing a damages suit against the state and AstraZeneca K.K., the Osaka-based Japanese subsidiary of British pharmaceutical company AstraZeneca PLC, the maker and distributor of the lung cancer drug Iressa, for alleged failure to inform doctors of the risk of serious side-effects.

E

CHINA-HAINAN-BOAO-BFA-ANNUAL CONFERENCE-SESSION (CN)

(220421) -- BOAO, April 21, 2022 (Xinhua) -- Leif Johansson, chair of the Board of Directors of AstraZeneca PLC, speaks during a session titled "Digital Economy For a Brighter Future" held during the Boao Forum for Asia Annual Conference 2022 in Boao, south China's Hainan Province, April 21, 2022. (Xinhua/Hu Zhixuan)

E

Vickie@Boao: China committed to helping world reduce vaccine divide

STORY: Vickie@Boao: China committed to helping world reduce vaccine divide DATELINE: April 21, 2022 LENGTH: 00:03:42 LOCATION: BOAO, China CATEGORY: ECONOMY SHOTLIST: 1. STANDUP 1 (English): VICKIE LI, Xinhua correspondent 2. STANDUP 2 (English): VICKIE LI, Xinhua correspondent 3. SOUNDBITE 1 (English): LEIF JOHANSSON, Chair of the Board of Directors of AstraZeneca PLC 4. SOUNDBITE 2 (English): SUDHEENDRA KULKARNI, Former chairman of Observer Research Foundation in India 5. SOUNDBITE 3 (English): RONNIE LINS, Director of China-Brazil Center for Research and Business in Brazil 7. SOUNDBITE 4 (Spanish): EDUARDO REGALADO, Senior researcher at International Policy Research Center of Cuba 8. STANDUP 3 (English): VICKIE LI, Xinhua correspondent STORYLINE: Vickie@Boao: What role does China play to narrow the vaccine divide? STANDUP 1 (English): VICKIE LI, Xinhua correspondent "The Boao Forum for Asia (BFA) annual conference is now underway here in China's Hainan Province." The BFA was founded in 2001. It's a no

E

Kin sue state, distributor over side-effects of Iressa cancer dr

TOKYO, Japan - Akio Chikazawa speaks to reporters in Tokyo on Nov. 25 after filing a damages suit against the state and AstraZeneca K.K., the Osaka-based Japanese subsidiary of British pharmaceutical company AstraZeneca PLC, the maker and distributor of the lung cancer drug Iressa, for alleged failure to inform doctors of the risk of serious side-effects. (Kyodo)

E

Japan's top gov't spokesman Kato?

TOKYO, Japan Kyodo - Japanese Chief Cabinet Secretary Katsunobu Kato attends a press conference in Tokyo on Jan. 25, 2021. Japan is set to receive 310 million vaccine doses from two U.S. pharmaceutical companies, Pfizer Inc. and Moderna Inc., and Britain's AstraZeneca Plc. The total will be enough for 157 million people. Medical workers are expected to be eligible for vaccination first, followed by people aged 65 or older, then people with pre-existing conditions and those caring for the elderly. While the central government is in charge of securing vaccines, inoculation will be left to local governments.

E

Japan's health minister after AstraZeneca files for vaccine approval

Japanese health minister Norihisa Tamura speaks in Tokyo on Feb. 5, 2021, after Britain's AstraZeneca Plc filed a request for his ministry to approve its novel coronavirus vaccine.

E

Japan's health minister after AstraZeneca files for vaccine approval

Japanese health minister Norihisa Tamura speaks in Tokyo on Feb. 5, 2021, after Britain's AstraZeneca Plc filed a request for his ministry to approve its novel coronavirus vaccine.

E

Japan's donation of COVID-19 vaccine to Vietnam

COVID-19 vaccine donated by Japan arrives at an airport in Hanoi on June 16, 2021. The plane carried 1 million coronavirus vaccine doses, developed by AstraZeneca Plc.

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Hideki Shimizu (R), a plaintiff who demanded compensation over side effects caused by the lung cancer drug Iressa, speaks at a press conference in Osaka on Feb. 25, 2011, together with Akio Chikazawa, a plaintiff in a similar suit filed in Tokyo. The Osaka District Court the same day ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine out of 11 plaintiffs, including Shimizu. (Kyodo)

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Supporters of plaintiffs hold up banners in front of the Osaka District Court on Feb. 25, 2011, declaring victory in their case after the court ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine of 11 plaintiffs who sought compensation over side-effects caused by the lung cancer drug Iressa. (Kyodo)

E

Plaintiffs of Iressa cancer drug case

TOKYO, Japan - Three deceased patients' relatives who sued the Japanese government and the Japanese unit of British pharmaceutical company AstraZeneca PLC, demanding compensation for the side effects caused by the lung cancer drug Iressa, walk to the Tokyo High Court on Nov. 15, 2011. The high court on the same day ruled the government and AstraZeneca K.K. are not responsible for damages, overturning a lower court ruling. The plaintiffs sought a combined 77 million yen in compensation. (Kyodo)

E

Japan panel approves Moderna, AstraZeneca COVID-19 vaccines

Japanese health minister Norihisa Tamura meets the press in Tokyo on May 20, 2021, after a health ministry panel approved COVID-19 vaccines developed by Moderna Inc. and AstraZeneca Plc.

E

Japan gov't panel approves Moderna, AstraZeneca COVID-19 vaccines

Photo taken at Kansai airport in Osaka Prefecture on April 30, 2021, shows cargo containing the first Japan-allocated batch of Moderna Inc.'s COVID-19 vaccine unloaded from a Japan Airlines plane upon its arrival from Belgium. A Japanese health ministry panel approved COVID-19 vaccines developed by Moderna Inc. and AstraZeneca Plc on May 20.

E

Japan panel approves Moderna, AstraZeneca COVID-19 vaccines

Japanese health minister Norihisa Tamura meets the press in Tokyo on May 20, 2021, after a health ministry panel approved COVID-19 vaccines developed by Moderna Inc. and AstraZeneca Plc.

E

Japan panel approves Moderna, AstraZeneca COVID-19 vaccines

Japanese health minister Norihisa Tamura meets the press in Tokyo on May 20, 2021, after a health ministry panel approved COVID-19 vaccines developed by Moderna Inc. and AstraZeneca Plc.

E

Japan panel approves Moderna, AstraZeneca COVID-19 vaccines

Japanese health minister Norihisa Tamura meets the press in Tokyo on May 20, 2021, after a health ministry panel approved COVID-19 vaccines developed by Moderna Inc. and AstraZeneca Plc.